Catalog # 10-2181

VX-702

CAS# 745833-23-2

6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide

Lot # X106735



A potent and selective inhibitor of p38 MAP kinases, p38α MAPK and p38β (K_D = 3.7 and 17 nM respectively).[1] Inhibits IL-6, IL-1β and TNFα production in LPS-primed blood.[1] Inhibits p38 in platelets stimulated by thrombin, collagen or thromboxane agonist U-46619 at 1 μM.[2] Provides only modest clinical efficacy in rheumatoid arthritis.[3,4] Delays platelet lesions and leads to better maintenance of stored platelets.[5]

1) Goldstein *et al*. (2010), *Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders*; J. Med. Chem., **53** 2345
2) Kuliopulos *et al*. (2004), *Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation*; Thromb. Haemostasis, **92** 1387
3) Damianov *et al*. (2009), *Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies*; Arthrit. Rheumat., **60** 1232
4) Ding *et al*. (2006), *Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome*; Curr. Opin. Investig. Drugs, **7** 1020
5) Scripchenko *et al*. (2013), *An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion*; PLoS One, **8(8)e** 70732

PHYSICAL DATA

Molecular Weight:	404.32
Molecular Formula:	$C_{19}H_{12}F_4N_4O_2$
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 40 mg/ml) or Ethanol (up to 2 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com